toxylact: a04ad10 Dronabinol
The first professional lActological database in the word
Dronabinol (ATC A04AD10) is a synthetic cannabinoid antiemetic and appetite stimulant that is contraindicated in breastfeeding due to psychoactive central nervous system effects and insufficient safety data in lactating women and infants.medpedia.framar+5
ATC class and pharmacological profile
Dronabinol is the pharmaceutical name for
synthetic delta‑9‑tetrahydrocannabinol
(THC), classified in ATC group A04AD10 “Other antiemetics
and antinauseants”
within the gastrointestinal system and metabolism section.wikipedia+3
It acts as a partial agonist at cannabinoid CB1 receptors in
the central
nervous system and gastrointestinal tract, modulating
neurotransmitter release
and inhibiting emetic signaling pathways.ncbi.nlm.nih+2
Antiemetic effects are mediated through CB1‑dependent
inhibition of 5‑HT3
(serotonin) receptors and reduced gastrointestinal motility,
while psychoactive
effects reflect its CNS cannabinoid activity.cannabisevidence+1
Indications in adults
ATC A04AD10 medicines containing dronabinol
are indicated for
anorexia associated with weight loss in patients with AIDS
and for nausea and
vomiting associated with cancer chemotherapy in adults who
have failed standard
antiemetic therapy.camberpharma+5
Appetite stimulation and reduction of nausea and emesis are
the clinically
relevant therapeutic outcomes.rcsb+3
Off‑label use has been explored for obstructive sleep apnea
and other
conditions, but these indications remain investigational and
are not part of
the formal A04AD10 class labeling.prescriberpoint+1
Dosage and administration (non‑lactation)
Dronabinol is administered orally as capsules
or oral solution,
usually starting at 2.5 mg twice daily for AIDS‑related
anorexia, with
titration in small increments based on clinical response and
tolerability.medpedia.framar+2
In chemotherapy‑induced nausea and vomiting, dosing is
weight‑based (mg/m²),
initiated 1–3 hours before chemotherapy and repeated every
2–4 hours, up to 4–6
doses per day, with maximum single doses around 12.6–15
mg/m² depending on
formulation.ncbi.nlm.nih+2
Marked interindividual variability in pharmacodynamic
effects requires cautious
titration and close monitoring, especially in the elderly
and in patients with
cardiovascular or psychiatric comorbidities.camberpharma+2
Toxicological profile
Dronabinol produces dose‑related central
nervous system toxicity
with neuropsychiatric manifestations such as dizziness,
euphoria, anxiety,
paranoia, hallucinations, depersonalization, and abnormal
thinking.accessdata.fda+4
Sedation, somnolence, ataxia, and visual disturbances
(including blurred
vision) are common and may impair psychomotor performance
and driving ability.pdf.hres+3
Cardiovascular effects include tachycardia, orthostatic
hypotension, and
potential exacerbation of underlying heart disease,
necessitating caution in
patients with cardiovascular disorders.pdf.hres+2
From a broader toxicological perspective,
chronic exposure to THC‑containing
products has been associated with cognitive impairment, mood
changes, and
potential effects on brain development, which are of
particular concern for
fetuses and infants.fda+1
Overdose may present with severe anxiety, agitation,
psychosis‑like symptoms,
marked tachycardia, and pronounced neurocognitive
impairment; management is
supportive with close observation and symptomatic treatment.ncbi.nlm.nih+2
Dependence and misuse potential exist due to psychoactive
properties, although
dronabinol is typically prescribed under controlled
conditions for limited
indications.accessdata.fda+2
Contraindications and precautions (general)
Dronabinol is contraindicated in patients with
known
hypersensitivity to the active substance or formulation
components.medpedia.framar+2
It should be used with great caution in individuals with
psychiatric disorders
(e.g. psychosis, severe anxiety), in those with significant
cardiovascular
disease, and in older adults, where CNS adverse effects are
more frequent and
severe.camberpharma+2
Concomitant CNS depressants (e.g. benzodiazepines, opioids,
alcohol) may
potentiate sedation and psychomotor impairment, increasing
overall toxicity
risk.pdf.hres+2
Lactation and breastfeeding risk assessment
Transfer into breast milk and infant exposure
THC and THC‑like cannabinoids, including
dronabinol, are
lipophilic and distribute into fatty tissues and human milk,
with detectable
levels in breast milk for several days after maternal use.lllc+1
Available data suggest that breast milk can contain
measurable THC up to
approximately 6 days after maternal consumption, indicating
prolonged potential
exposure for the breastfed infant.cdc
Although direct quantitative pharmacokinetic data for
synthetic dronabinol in
human milk are limited, extrapolation from cannabis and THC
studies strongly
supports milk transfer and infant exposure.pubmed.ncbi.nlm.nih+3
Effects on the breastfed infant
Robust, controlled studies of dronabinol in
breastfeeding dyads
are lacking, and current evidence does not conclusively
define a safe exposure
threshold for infants.pubmed.ncbi.nlm.nih+2
Potential infant risks inferred from THC data include
adverse effects on
neurodevelopment, such as impaired cognition, altered
behavior, and long‑term
consequences related to disrupted brain maturation.fda+1
Minor acute effects such as sedation, feeding difficulties,
or altered
responsiveness are considered biologically plausible given
the drug’s CNS
activity, but have not been adequately characterized in
systematic lactation
studies.lllc+2
Maternal safety during lactation
In lactating women, dronabinol may impair
judgment, reaction
time, and psychomotor skills, which can compromise safe
infant care.cdc+3
Neuropsychiatric adverse reactions (anxiety, paranoia,
hallucinations,
depersonalization) pose additional risks for the
mother–infant interaction and
caregiving quality.medpedia.framar+3
Given the absence of clear therapeutic indications in the
postpartum period
that outweigh these risks, routine use in breastfeeding
mothers is not
justified.pubmed.ncbi.nlm.nih+3
Recommendations from authorities and professional bodies
Regulatory authorities and expert
organizations strongly advise
against the use of THC‑containing products, including
prescription dronabinol,
during pregnancy and breastfeeding.lllc+3
The U.S. FDA explicitly recommends avoiding THC and
dronabinol in all forms
while breastfeeding, citing potential serious risks and lack
of adequate safety
data.fda
Public health agencies emphasize that, due to insufficient
evidence of safety
and plausible harm, breastfeeding mothers should refrain
from cannabis and
cannabinoid use; if use persists, at minimum a substantial
reduction in dose
and avoidance of infant second‑hand smoke exposure are
advised.cdc+2
Toxicological‑lactological classification for A04AD10 (dronabinol)
For your database, the overall toxicological‑lactological assessment for dronabinol‑containing medicines in ATC class A04AD10 can be summarized as follows:ncbi.nlm.nih+6
· Lactation safety category: Contraindicated / not recommended in breastfeeding.
· Primary concern: Psychoactive CNS effects and potential negative impact on infant neurodevelopment; transfer of lipophilic THC‑like compound into breast milk with days‑long detectability.
· Use in breastfeeding: Avoid; if maternal cannabinoid exposure cannot be prevented, individualized counseling must weigh the benefits of breastfeeding against unquantified but plausible neurodevelopmental risks, with close infant monitoring.
· Preferred alternatives: For chemotherapy‑induced nausea and vomiting in lactating women, evidence‑based non‑cannabinoid antiemetics (e.g. serotonin 5‑HT3 antagonists, dopamine antagonists, antihistamines) should be considered according to oncology and lactation guidelines.atcddd.fhi+1
Brief example clinical statement
“In lactating women, dronabinol‑containing antiemetic therapy is not recommended because of infant exposure to a psychoactive cannabinoid via breast milk and the absence of reassuring safety data; alternative non‑cannabinoid antiemetics are preferred.”



